Text Correction
There was an error in the original publication [1].
Original text:
“For all other target proteins, the primary antibody incubation was performed for 1 h at room temperature with a 1:4000 dilution in 1% BSA/PBS for p16 INK4a (ab51243; abcam, Cambridge, UK), a 1:700 dilution in 1% BSA/PBS for pRb (ab181616; abcam, Cambridge, UK), and a 1:125 dilution in 1% BSA/PBS for CyclinD1 (ab16663; abcam, Cambride, UK).”
A correction has been made to Section 2.2 Immunohistochemistry; the corrected text is as follows:
“For all other target proteins, the primary antibody incubation was performed for 1 h at room temperature with a 1:4000 dilution in 1% BSA/PBS for p16 INK4a (ab54210; abcam, Cambridge, UK), a 1:700 dilution in 1% BSA/PBS for pRb (ab181616; abcam, Cambridge, UK), and a 1:125 dilution in 1% BSA/PBS for CyclinD1 (ab16663; abcam, Cambridge, UK).”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Kühn, J.P.; Schmid, W.; Körner, S.; Bochen, F.; Wemmert, S.; Rimbach, H.; Smola, S.; Radosa, J.C.; Wagner, M.; Morris, L.G.T.; et al. HPV Status as Prognostic Biomarker in Head and Neck Cancer—Which Method Fits the Best for Outcome Prediction? Cancers 2021, 13, 4730. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.